key: cord-0694604-qe00xbmd
authors: Gutiérrez López de Ocáriz, Xabier; Castro Quismondo, Nerea; Vera Guerrero, Elena; Rodríguez Rodríguez, Mario; Ayala Díaz, Rosa; Martínez López, Joaquín
title: Thrombosis and antiphospholipid antibodies in patients with SARS‐COV‐2 infection (COVID‐19)
date: 2020-08-26
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13320
sha: 4020c3baaa3b15a305fd8e65103b26131f219547
doc_id: 694604
cord_uid: qe00xbmd

nan

To the Editor:

In March 2020, the infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was declared a pandemic by the World Health Organization. This global health emergency had in Spain one of its epicenters.

As the scientific community gained clinical experience about COVID-19 (coronavirus disease 2019) and more and more clinical reports were published, an increased thrombotic risk was observed in patients infected with this novel virus. Subsequently, this hypothesis was confirmed with the performance of the first autopsies, being deep vein thrombosis and massive pulmonary embolisms common findings.

Several references exist in the literature to the possible relation between the presence of a lupus anticoagulant (LA) and the prothrombotic state experienced by these patients. 1, 2 In our center, we retrospectively analyzed 27 patients who had been tested for antiphospholipid antibodies between March 13th and April 26th of 2020, during their hospital admission due to COVID-19 (confirmed by a positive RT-PCR for SARS-CoV-2 in a nasopharyngeal swab). Informed consent was obtained, and no change in clinical practice was made according to the results. All of them were on prophylactic heparin, and the determinations were made 24 hours after the last dose. Their clinical and laboratory characteristics are described in Table 1 We agree with Beyrouti R et al, 7 considering a prolonged aPTT not a very sensitive test to predict the possible positivity of LA, because of the potential interference of other factors that can shorten (such as factor VIII) or prolong it (such as factor XII or C-reactive protein).

In conclusion, according to our experience, LA determination may be unnecessary for COVID-19 patients due to its high variability in acute infections and its lack of predictive capability of thrombotic 2 | LETTER TO THE EDITOR risk, except in critical patients whose clinical situation is already an additional risk factor.

All SARS-CoV-2-infected patients should receive antithrombotic prophylaxis regardless of the presence of LA due to their increased thrombotic risk as a consequence of multiple factors (hyperinflammation, platelet activation, and endothelial dysfunction) and its positivity should not change this practice.

We would like to thank all patients and families for their fight against this pandemic.

None of the authors have any conflict of interest in relation to the information reported here. 

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Lupus Anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results?

Coagulopathy and Antiphospholipid Antibodies in Patients With Covid-19

Lupus anticoagulant is frequent in patients with covid-19

Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19

Coagulopathy of COVID-19 and antiphospholipid antibodies

Characteristics of Ischaemic Stroke Associated With COVID-19

Gutiérrez López de Ocáriz X., Castro Quismondo N., and Vera Guerrero E. collected the date processed statistics and wrote the manuscript. Rodríguez Rodríguez M., Ayala Díaz R., and Martínez López J. revised the manuscript.